Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576496 · ClinicalTrials.gov registry record · Phase 1
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 study of Multiple Myeloma and Cutaneous T Cell Lymphoma, sponsored by Mundipharma Research Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
- 18
- Study locations
NCT02576496 is a Phase 1 study of Multiple Myeloma and Cutaneous T Cell Lymphoma that has completed, run by Mundipharma Research Limited. The registered enrollment target is 106 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 18 study locations across 6 states.
The verdict
NCT02576496, a Phase 1 study of Multiple Myeloma and Cutaneous T Cell Lymphoma, has completed, sponsored by Mundipharma Research Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.
Conditions Studied
Interventions
- DRUG Tinostamustine
Study Locations (18)
Other
- CHU de Caen - Caen
- CHU ESTAING Service de thérapie Cellulaire et hématologique Clinique - Clermont-Ferrand
- CHU Lille Service des Maladies du Sang - Lille
- Hopital Haut Leveque - Pessac
- Centre hospitalier Lyon Sud - Pierre-Bénite
- University Hospital of Ulm, Department of Internal Medicine III - Ulm
- Institute of Hematology "L. A. Seràgnoli", University of Bologna - Bologna
- National Cancer Institute, Fondazione 'G. Pascale' - Naples
- VU medisch centrum - Amsterdam
- Erasmus MC - Rotterdam
- Hospital Universitario de Salamanca - Salamanca
- Hospital Universitario Marqués de Valdecilla - Santander
- Kantonsspital St.Gallen - Sankt Gallen
Arizona
- Mayo Clinic - Phoenix
Florida
- Mayo Clinic Cancer Center - Jacksonville
New York
- Columbia University Medical Center - New York
Ohio
- University Hospitals Cleveland Seidman Cancer Center - Cleveland
Barcelona
- Institut Català d'Oncologia de Barcelona - L'Hospitalet de Llobregat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576496
The ClinicalTrials.gov registry entry for NCT02576496 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (81% lower). The listed sponsor is Mundipharma Research Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Tinostamustine is the first listed.
NCT02576496 reports 18 study locations spanning 6 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT02576496 about?
NCT02576496 is a clinical study titled "Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies". This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.
What is the current status of trial NCT02576496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2016-04-14. Estimated completion is 2023-11-21.
What conditions does trial NCT02576496 study?
This clinical trial studies the following conditions: Multiple Myeloma, Cutaneous T Cell Lymphoma, Hodgkin's Lymphoma, Hematological Malignancies.
What interventions are being tested in trial NCT02576496?
The interventions under investigation include: Tinostamustine (DRUG).
Who is sponsoring clinical trial NCT02576496?
This trial is sponsored by Mundipharma Research Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02576496 being conducted?
This trial has 18 study locations across Arizona, Florida, New York, Ohio, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.